Skip to main content
SpringerLink
Log in

Somatostatin Analogues in Pituitary Adenomas

  • Chapter
Peptides in Oncology II

Part of the book series: Recent Results in Cancer Research ((RECENTCANCER,volume 129))

Abstract

Evidence that the secretion of growth hormone (GH) is under the dual control of a hypothalamic stimulating hormone — growth hormone releasing hormone (GHRH) — and an inhibitory factor was already presented by Krulich et al. in 1968. However, only in 1973 did Brazeau et al. isolate a tetradecapeptide from ovine hypothalami that inhibited GH or somatotropin secretion. The peptide was called somatostatin or growth-hormone release-inhibiting hormone.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Barkan AL, Kelch RP, Hopwood NJ, Beitins IZ (1988) Treatment of acromegaly with the long-acting Somatostatin analog SMS 201–995. J Clin Endocrinol Metab 66: 16–23

    Article  PubMed  CAS  Google Scholar 

  • Bauer W, Briner U, Doepfner W, Haller R, Huguenin R, Marbach P et al (1982) SMS 201–995: a very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sci 31: 133–140

    Article  Google Scholar 

  • Beckers A, Abs R, Mahler C, Vandalem JL, Pirens G, Hennen G, Stevenaert A (1991) Thyrotropin secreting pituitary adenomas: Report of seven cases. J Clin Endocrinol Metab 72: 477–483

    Google Scholar 

  • Beck-Peccoz P, Mariotti S, Guillauseau PJ, Medri G, Piscitelli G, Bertoli A, Barbarino A, Rondena M, Chanson Ph, Pinchera A, Faglia G (1989) Treatment of hyperthyroidism due to inappropriate secretion of thyrotropin with the somatostatin analogue SMS 201–995. J Clin Endocrinol Metab 68: 208–214

    Article  PubMed  CAS  Google Scholar 

  • Bertagna X, Favrod-Coune C, Escourolle H et al (1989) Suppression of ectopic adrenocorticotropin secretion by the long-acting somatostatin analogue octreotide. J Clin Endocrinol Metab 68: 988–991

    Article  PubMed  CAS  Google Scholar 

  • Besser GM (1992) In: Liuzzi A, Sobrinho LG, Besser GM (eds) Proceedings of the Workshop “Practical Approaches to the Diagnosis and Treatment of Acromegaly”. Metabolism 41 [Suppl 2]: 87–90

    Google Scholar 

  • Besser GM, Wass JAH (1987) The use of dopamine agonists in the management of acromegaly. In: Robbins RJ, Melmed S (eds) Acromegaly. Plenum, New York, pp 261266

    Google Scholar 

  • Bevan JS, Webster J, Burke CW, Scanlon MF (1992) Dopamine agonists and pituitary tumour shrinkage. Endocr Rev 13: 220–240

    PubMed  CAS  Google Scholar 

  • Brazeau P, Vale W, Burgus R, Ling N, Butcher M, Rivier J, Guillemin R (1973) Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science 179: 77–79

    Article  PubMed  CAS  Google Scholar 

  • Buscail L, Tauber JP, Puet-Bosquet L et al (1989) Gallstones and treatment with octreotide for acromegaly. BMJ 299: 1162

    Google Scholar 

  • Chan AW, MacFarlane IA, van Heyningen C et al (1990) Clinical hyperthyroidism due to non-neoplastic inappropriate thyrotropin secretion. Postgrad J Med 66: 743–746

    Article  CAS  Google Scholar 

  • Chanson P, Warnet A (1992) Treatment of thyroid-stimulating hormone-secreting adenomas with octreotide. Metabolism 41 [Suppl 21: 62–65

    Google Scholar 

  • Chiodini PG, Attanasio R, Orlandi P, Cozzi R (1991) Growth hormone release inhibiting hormone. In: Motta M (ed) Brain endocrinology, 2nd edn. Raven, New York, pp 301–313

    Google Scholar 

  • Chiodini PG, Cozzi R, Dallabonzana D, Oppizzi G, Verde G, Petrocini M, Liuzzi A, del Pozo E (1987) Medical treatment of acromegaly with SMS 201–995, a somatostatin analogue: a comparison with bromocriptine. J Clin Endocrinol Metab 64: 447–453

    Article  PubMed  CAS  Google Scholar 

  • Ching LJC, Sandler LM, Kraenzlin ME, Burrin JM, Joplin GF, Bloom SR (1985) Long term treatment of acromegaly with a long-acting analogue of somatostatin. BMJ 290: 284–287

    Article  Google Scholar 

  • Christensen SE, Weeke J, Orskov H, Moller N, Flyvbjerg A, Harris AG, Lund E, Jorgensen J (1987) Continuous subcutaneous pump infusions of somatostatin analogue 201–995 versus subcutaneous injection schedule in acromegalic patients. Clin Endocrinol 27: 297–306

    Article  CAS  Google Scholar 

  • Chrubasik J, Meynadier J, Blond S et al. (1984) Somatostatin: a potent analgesic. Lancet 2:1208–1209

    Google Scholar 

  • Comi RJ, Gesundheit N, Murray L, Gorden P, Weintraub BD (1987) Response of thyrotropin-secreting pituitary adenomas to a long-acting somatostatin analogue. N Engl J Med 317: 12–17

    Article  PubMed  CAS  Google Scholar 

  • Dowling RH, Hussaini SH, Murphy GM, Besser GM, Wass JAH (1992) Gallstones during octreotide therapy. Metabolism 41 [Suppl 2]: 22–33

    Article  PubMed  CAS  Google Scholar 

  • Ezzat S, Ren S-G, Braunstein GD, Melmed S (1992) Octreotide stimulates Insulin-like growth factor binding protein-1: a potential pituitary independent mechanism for drug action. J Clin Endocrinol Metab 75: 1459–1463

    Article  PubMed  CAS  Google Scholar 

  • Faglia G, Bazzoni N, Spada A, Arosio M, Ambrosi B, Spinelli F, Sara R, Bonino C, Lunghi F (1991) In vivo detection of somatostatin receptors in patients with functionless pituitary adenomas by means of a radioiodinated analogue of somatostatin (123SDZ 204090). J Clin Endocrinol Metab 73: 580–856

    Article  Google Scholar 

  • Guillausseau PJ, Chanson P, Timsit J et al (1987) Visual improvement with SMS 201–995 in a patient with a thyrotropin-secreting adenoma. N Engl J Med 317: 53–54

    Article  PubMed  CAS  Google Scholar 

  • Halse J, Harris AG, Kvistborg A, Kjartansson O, Smiseth O, Djosland O, Hass G, Jervell J (1990) A randomized study of SMS 201–995 versus bromocriptine treatment in acromegaly: clinical and biochemical effects. J Clin Endocrinol Metab 70: 1254–1261

    Article  PubMed  CAS  Google Scholar 

  • Harris A (1991) Acromegaly. Sandoz, Basel Harris AG, Prestele H, Herold K, Boerlin V (1988) Long-term efficacy of Sandostatin (SMS 201–995, octreotide) in 178 acromegalic patients: results from the international multicen-42 K. von Werder ter acromegaly study group. In: Lamberts SWJ (eds) Sandostatin in the treatment of acromegaly. Springer, Berlin, Heidelberg New York, pp 117–125

    Google Scholar 

  • Heron L, Thomas F, Ruiz JM, Henan S, Schatz B, Kuhn JM (1992) Treatment of acromegaly with a longacting formulation of the somatostatin analogue laureotide. One year follow up. Abstract 714, Endocrine Society San Antonio, Texas

    Google Scholar 

  • Holland LJ, van Koetsveld PM, van Vroonhoven CCJ, Stefanko SZ, Lamberts SWJ (1989) Heterogeneity of growth hormone (GH) release by individual pituitary adenoma cells from acromegalic patients, as determined by the reverse hemolytic plaque assay: effects of SMS 201–995, GH-releasing hormone and thyrotropin releasing hormone. J Clin Endocrinol Metab 68: 613–620

    Google Scholar 

  • Horn K, Erhardt F, Fahlbusch R, Pickardt CR, von Werder K, Scriba PC (1976) Recurrent thyrotoxic goiter and galactorrhea-amenorrhea syndrome due to an autonomous thyrotropin and prolactin producing pituitary adenoma. J Clin Endocrinol 43: 142

    Article  Google Scholar 

  • James R, Chatterjee S, White MC, Hall K, Moller N, Kendall-Taylor P (1989) Continuous infusion of octreotide in acromegaly. Lancet 2: 1083–1087

    Article  PubMed  CAS  Google Scholar 

  • Krulich I, Dhariwal APS, McCann SM (1968) Stimulatory and inhibitory effects of purified hypothalamic extracts on growth hormone release from rat pituitary in vitro. Endocrinology 83: 783–790

    Article  PubMed  CAS  Google Scholar 

  • Lamberts SWJ, Bakker WM, Reubi JC (1990) The value of somatostatin receptor imaging in the localization of endocrine and brain tumours. N Engl J Med 323: 1246–1249

    Article  PubMed  CAS  Google Scholar 

  • Lamberts SWJ, Uitterlinden P, Verschoor L, van Dorgen KJ, del Pozo E (1985) Longterm treatment of acromegaly with the somatostatin analogue SMS 201–995. N Engl J Med 313: 1576–1580

    Article  PubMed  CAS  Google Scholar 

  • Lamberts SWJ, Zweens M, Klijn JGM, van Vroohoven CCJ, Stefanko SZ, del Pozo E (1986) The sensitivity of growth hormone and prolactin secretion to the somatostatin analogue SMS 201–995 in patients with prolactinomas and acromegaly. Clin Endocrinol 25:201–212

    Google Scholar 

  • Lamberts SWJ, Uitterlinden P, del Pozo E (1987) SMS 201–995 induces a continuous decline in circulating growth hormone and somatomedin-C levels during therapy of acromegalic patients for over two years. J Clin Endocrinol Metab 65: 703–710

    Article  PubMed  CAS  Google Scholar 

  • Lamberts SWJ, Uitterlinden P, Schujff PC, Klijn JGM (1988) Therapy of acromegaly with Sandostatin: the predictive value of an acute test, the value of serum somatomedin C measurements in dose adjustment and the definition of a biochemical `cure’. Clin Endocrinol (0x0 289: 411–420

    Article  Google Scholar 

  • Lamberts SWJ, Uitterlinden P, Klijn JMG (1989) The effect of the longacting somatostatin analogue SMS 201–995 on ACTH secretion in Nelson’s Syndrome and Cushing’s Syndrome. Acta Endocrinol 120:760–766

    Google Scholar 

  • Liuzzi A, Chiodini PG, Botalla L, Cremascoli G, Müller EE, Silvestrini F (1974) Decrease of plasma growth hormone (GH) levels in acromegalics following CB 1542 Br alpha-ergocryptine) administration. J Clin Endocrinol Metab 38: 910–912

    Google Scholar 

  • Liuzzi A, Dallabonzana D, Oppizzi G, Cozzi R, Strada S, Arrigoni GL, Chiodini PG (1991) Is there a real medical treatment for the “non-secreting” pituitary adenomas? In: Faglia G, Beck-Peccoz P, Ambrosi B, Travaglini P, Spada A (eds) Pituitary adenomas: new trends in basic and clinical research. ICS 961, Elsevier, Amsterdam, pp 383–390

    Google Scholar 

  • Losa M, Oeckler B, Schopohl J, Müller OA, Alba-Lopez J, von Werder K (1989) Evaluation of selective transsphenoidal adenomectomy by endocrinological testing and somatomedinC measurement in acromegaly. J Neurosurg 70: 561–567

    Article  PubMed  CAS  Google Scholar 

  • Lorcy Y, Delambre C, Leguerrier AM et al (1989) Traitement de la maladie de Cushing par un analogue de la somatostatine (SMS 201–995): Quatres observations. Ann Endocrinol 50: 311 (Abstr 106)

    Google Scholar 

  • Mehltretter G, Heinz S, Schopohl J, von Werder K, Müller OA (1991) Long-term treatment with SMS 201–995 in resistant acromegaly: effectiveness of high doses and continuous subcutaneous infusion. Klin Wochenschr 69: 83–90

    Article  PubMed  CAS  Google Scholar 

  • Müller OA, von Werder K (1992) Ectopic production of ACTH and corticotropin-releasing hormone (CRH). J Steroid Biochem Mol Biol 43: No. 5, 403–408

    Article  PubMed  Google Scholar 

  • Muhr C, Bergström M, Lundberg PO, Bergström K, Langström B (1988) Positron emission tomography for the in vivo characterization and follow-up of treatment in pituitary adenomas. Adv Biosci 69: 163–170

    Google Scholar 

  • Petrini L, Pilosu R, Marcello A, Mastio F, Bartolomei MP, Nardi M, Martino E (1990) Effect of octreotide (SMS 201–995) administration on the size of nonfunctional pituitary tumours. J Endocrinol Invest 13 [Suppl 1] :161

    Google Scholar 

  • Pieters GFFM, Van Liessum PA, Smals AGH et al (1987) Longterm treatment of acromegaly with Sandostatin (SMS 201–995). Normalization of most anomalous growth hormone responses. Acta Endocrinol [Suppl] 18: 9–18

    Google Scholar 

  • Plöckinger V, Dienemann D, Quabbe H-J (19990) Gastrointestinal side-effects of octreotide during long-term treatment of acromegaly. J Clin Endocrinol Metab 71:1658–1662

    Google Scholar 

  • Quabbe Hi (1982) Treatment of acromegaly by transsphenoidal operation, 90-yttrium implantation and bromocriptine: results in 230 patients. Clin Endocrinol (Oxf) 16: 107–119

    Article  Google Scholar 

  • Quabbe HJ, Plöckinger U (1989) Dose-response study and long-term effect of the somatostatin analogue octreotide in patients with therapy-resistant acromegaly. J Clin Endocrinol Metab 68: 873–881

    Article  PubMed  CAS  Google Scholar 

  • Reichlin S (1983) Somatostatin. N Engl J Med 309:1495–1501, 1536–1563

    Google Scholar 

  • Renard E, Barjon JN, Bringer J, Frèrebeau P, Jaffiol C (1990) Quick improvement of visual field complications due to extensive nonfunctioning hypothalamic or pituitary tumours with a somatostatin analogue (SMS 201–995). J Endocrinol Invest 13 [Suppl 2]: 74

    Google Scholar 

  • Reschini E, Giustina G, Cantalamessa L, Peracchi M (1976) Hyperthyroidism with elevated plasma TSH levels and pituitary tumor: Study with somatostatin. J Clin Endocrinol Metab 43: 924–927

    Google Scholar 

  • Reubi JC, Landolt AM (1989) The growth hormone responses to octreotide in acromegaly correlate with adenoma somatostatin receptor status. J Clin Endocrinol Metab 68:844–850

    Google Scholar 

  • Reubi JC, Heitz PU, Landolt AM (1987) Visualization of somatostatin receptors and corre-lation with immunoreactive growth hormone and prolactin in human pituitary ade-nomas: evidence for different tumor subclasses. J Clin Endocrinol Metab 65: 65–73

    Article  PubMed  CAS  Google Scholar 

  • Ross DA, Wilson CB (1988) Results of transsphenoidal microsurgery for growth hormone secreting pituitary adenomas in a series of 214 patients. J Neurosurg 68: 854–867

    Article  PubMed  CAS  Google Scholar 

  • Sano T, Ma SL, Kovacs K (1991) Growth hormone releasing hormone producing tumours: clinical, biochemical and morphological manifestations. Endocr Rev 9: 357–373

    Article  Google Scholar 

  • Sassolas G (1992) The role of sandostatins in acromegaly. Metabolism 41 [Suppl 2]: 39–43

    Article  PubMed  CAS  Google Scholar 

  • Sassolas G, Melmed S (1992) Symposium: basic somatostatin research. Metabolism 41 [Suppl 2]: 11–16

    Article  PubMed  CAS  Google Scholar 

  • Sassolas G, Serusclat P, Claustrat B, Trouillas J, Merabt S, Cohen R, Souquet JC (1988) Plasma alpha-subunit levels during the treatment of pituitary adenomas with the somatostatin analogue SMS 201–995. Horm Res 29: 124–128

    Article  PubMed  CAS  Google Scholar 

  • Sassolas G, Harris AG, James-Deidier A (1990) Long term effect of incremental doses of the Somatostatin analogue SMS 201–995 in 58 acromegalic patients. J Clin Endocrinol Metab 71: 391–397

    Article  PubMed  CAS  Google Scholar 

  • Schopohl J, Wiedemann Y, Nass R, Strasburger A, Moyto J, Garzon F, Thomas F (1993) Treatment of resistant acromegaly: high dose octreotide therapy versus a slow release formulation of the somatostatin analogue lanreotide. Exper Clin Endocr (in press)

    Google Scholar 

  • Siler TM, Yen SSC, Vale W, Guillemin R (1974) Inhibition by somatostatin of the release of TSH induced in man by thyrotropin-releasing factor. J Clin Endocrinol Metab 38: 742–746

    Article  PubMed  CAS  Google Scholar 

  • Stalla GK, Stalla J, Mojito J, Höllt V, Oeckler R, Buchfelder M, Müller OA (1989) Regula-tion of corticotroph adenoma cells in vitro. Acta Endocrinol 190 [Suppl 1]: 209

    Google Scholar 

  • Stevenaert A, Harris AG, Kovacs K, Beckers A (1992) Presurgical octreotide treatment in acromegaly. Metabolism 41 [Suppl 2]: 51–58

    Article  PubMed  CAS  Google Scholar 

  • Vance ML, Harris AG (1991) Longterm treatment of 189 acromegalic patients with the somatostatin analogue octreotide. Arch Intern Med 151: 1573–1578

    Article  PubMed  CAS  Google Scholar 

  • Vos P, Croughs RJM, Thijssen JHH, van’t Verlaat JW, van Ginkel LA (1988) Response of luteinizing hormone-secreting pituitary adenomas to a long-acting somatostatin analogue. Acta Endocrinol 118: 587–590

    PubMed  CAS  Google Scholar 

  • Warnet A (1990) Effect of Sandostatin on optic chiasm compression due to non GH-, non TSH-secreting pituitary adenomas. J Endocrinol Invest 13 [Suppl 2]: 74

    Google Scholar 

  • Warnet A (1992) The Role of octreotide (Sandostatin) in Non-Growth Hormone-, Non-Thyroid-Stimulating Hormone-, and Non-Prolactin-Secreting Adenomas. Metabolism 41 [Suppl ]21:59–61

    Google Scholar 

  • Weintraub BD, Gershengorn MC, Kourides IA, Fein H (1981) Inappropriate secretion of thyroid-stimulating hormone. Ann Intern Med 95: 339–351

    Google Scholar 

  • von Werder K (1975) Wachstumshormon-und Prolaktin-Sekretion des Menschen. Urban and Schwarzenberg, Munich

    Google Scholar 

  • von Werder K, Faglia G (1992) Potential indications for octreotide in endocrinology. Metabolism 41 [Suppl 2]: 91–98

    Article  Google Scholar 

  • von Werder K, Fahlbusch R, Losa M, Oeckler R, Pichl J, Schopohl J (1987) Decision analysis of treatment options in acromegaly. In: Robbins RJ, Melmed S (eds) Acromegaly. Plenum, New York, pp 267–280

    Google Scholar 

  • von Werder K, Schopohl J, Wolfram G, Mojto J, Stalla GK, Losa M, Müller OA (1988) Ectopic production of pituitary hormones and releasing hormones. Adv Biosci 69: 87–95

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Schloßparkklinik, Freie Universität Berlin, Heubnerweg 2, 1000, Berlin 19, Germany

    K. von Werder

Authors
  1. K. von Werder
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Klinik für Innere Medizin II: Onkologie — Hämatologie — Endokrinologie — Stoffwechselerkrankungen, Klinikum der Friedrich-Schiller-Universität Jena, Erlanger Allee 101, O-6902, Jena-Lobeda, Germany

    K. Höffken

Rights and permissions

Reprints and permissions

Copyright information

© 1993 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

von Werder, K. (1993). Somatostatin Analogues in Pituitary Adenomas. In: Höffken, K. (eds) Peptides in Oncology II. Recent Results in Cancer Research, vol 129. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-84956-5_2

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-84956-5_2

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-84958-9

  • Online ISBN: 978-3-642-84956-5

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation